Views 556
Citations 0
Clinical Trials Update
October 23/30, 2013

Adding Cognitive-Behavioral Therapy to SRIs May Improve OCD Symptoms

Author Affiliations

Copyright 2013 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA. 2013;310(16):1665. doi:10.1001/jama.2013.281198

Adding cognitive-behavioral therapy to serotonin reuptake inhibitors (SRIs) to treat obsessive-compulsive disorder (OCD) was superior in reducing symptoms compared with adding an antipsychotic drug or placebo (Simpson HB et al. JAMA Psychiatry. doi:10.1001/jamapsychiatry.2013.1932 [published online September 11, 2013]).

Researchers randomized 100 adult patients with OCD, all of whom were taking SRIs, to receive 8 weeks of risperidone, 17 twice-weekly sessions of exposure and ritual prevention (EX/RP) cognitive-behavioral therapy, or placebo pills. More participants in the therapy group achieved minimal symptoms—42.5%, vs 12.5% for risperidone and 5% for placebo—as well as improved insight, functions, and quality of life. Risperidone was not significantly better than placebo on any outcome.

First Page Preview View Large
First page PDF preview
First page PDF preview